Avrobio

Avrobio Overview

Founded 2015
Founded
Status Public
Employees 112
Employees
Stock Symbol AVRO
Stock Symbol
Share Price $20.22 (As of Friday Closing)

Avrobio General Information

Description

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company manufactures products include AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher, Pompe, and Cystinosis.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • One Kendall Square
  • Building 300, Suite 201
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Avrobio Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Avrobio Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$20.22 $19.18 $9.76 - $29.32 $729M 36M 336K -$2.73

Avrobio Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 373,592 431,113 260,288
Revenue 0 0 0 0
EBITDA (83,802) (75,049) (47,707) (18,660)
Net Income (81,835) (72,965) (46,361) (18,648)
Total Assets 269,728 200,514 133,479 7,022
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Avrobio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Avrobio‘s full profile, request access.

Request a free trial

Avrobio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Avrobio‘s full profile, request access.

Request a free trial

Avrobio Competitors (60)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Kite Pharma Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
00000000 000000000 Formerly VC-backed Cambridge, MA 000 0000 000000 - 000 0000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000 00000000 Corporation Boston, MA 00 00000 00000000000 00000
00000000 Formerly VC-backed London, United Kingdom 000 00000 000000000 00000

Avrobio Executive Team (9)

Name Title Board Seat Contact Info
Geoff MacKay Chief Executive Officer, President & Board Member
Holly May Chief Commercial Officer
Deanna Petersen Executive
Jeffrey Medin Ph.D Co-Founder
Kim Warren Ph.D Head of Operations

2 Former Executives

Avrobio Board Members (8)

To view Avrobio‘s full board member team, request access >>
Name Representing Role Since
Annalisa Jenkins Self Board Member 000 0000
Bruce Booth Ph.D Atlas Venture Chairman & Board Member 000 0000
Christopher Paige Ph.D Avrobio Board Member 000 0000
Geoff MacKay Avrobio Chief Executive Officer, President & Board Member 000 0000
Ian Clark Avrobio Board Member 000 0000

1 Former Board Member

Avrobio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Avrobio‘s full profile, request access.

Request a free trial